Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy
- PMID: 26731722
- DOI: 10.1159/000442527
Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy
Abstract
Background: There are few background data on the impact of clinical factors on neurotoxicity and prognosis in patients treated with adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy.
Methods: 102 stage II high-risk and stage III colorectal cancer patients were treated for 6 months with adjuvant CAPOX, then they were followed up. Associations between clinical variables, metabolic syndrome components, smoking and neurotoxicity were evaluated by the x03C7;2 test. The Kaplan-Meier product limit method was applied to graph disease-free survival (DFS). Univariate analysis was done with the log-rank test. Cox's proportional hazards regression was used to analyze the effect of several risk factors on DFS.
Results: Significant associations were found between diabetes (p < 0.001), BMI (p = 0.01) and the occurrence of chronic neurotoxicity. After a median follow-up of 46 months, 14 patients (13.7%) had suffered recurrence. An analysis of the prognostic factors for DFS showed that prognosis is unfavorable for patients with high lymph-nodal involvement (HR: 5.23, p = 0.0007), diabetes (HR: 4.86; p = 0.03) and a BMI ≥25 (HR: 3.69, p = 0.002).
Discussion: Common mediators in diabetes and obesity could be involved in peripheral neuropathy and in stimulating micro-metastases. Further studies are necessary to explain this interesting connection between diabetes, obesity and colon cancer.
© 2016 S. Karger AG, Basel.
Similar articles
-
Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.Oncol Res. 2014;22(5-6):325-31. doi: 10.3727/096504015X14410238486522. Oncol Res. 2014. PMID: 26629945 Free PMC article.
-
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324362 Clinical Trial.
-
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.Asian Pac J Cancer Prev. 2015;16(6):2237-43. doi: 10.7314/apjcp.2015.16.6.2237. Asian Pac J Cancer Prev. 2015. PMID: 25824744
-
Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?Int J Cancer. 2018 Nov 15;143(10):2342-2350. doi: 10.1002/ijc.31616. Epub 2018 Aug 11. Int J Cancer. 2018. PMID: 29873066 Review.
-
Obesity and diabetes as prognostic factors in patients with colorectal cancer.Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S109-S114. doi: 10.1016/j.dsx.2016.12.018. Epub 2016 Dec 13. Diabetes Metab Syndr. 2017. PMID: 27989518 Review.
Cited by
-
Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.J Cancer Surviv. 2019 Aug;13(4):495-502. doi: 10.1007/s11764-019-00769-7. Epub 2019 Jun 6. J Cancer Surviv. 2019. PMID: 31172429
-
Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.Support Care Cancer. 2023 Oct 28;31(12):660. doi: 10.1007/s00520-023-08134-2. Support Care Cancer. 2023. PMID: 37897532 Free PMC article.
-
Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.Brain Behav. 2019 Jun;9(6):e01312. doi: 10.1002/brb3.1312. Epub 2019 May 7. Brain Behav. 2019. PMID: 31063261 Free PMC article.
-
2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.Oncotarget. 2017 Mar 14;8(11):18456-18485. doi: 10.18632/oncotarget.14472. Oncotarget. 2017. PMID: 28060743 Free PMC article. Review.
-
Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.J Pain Symptom Manage. 2017 Nov;54(5):701-706.e1. doi: 10.1016/j.jpainsymman.2017.07.033. Epub 2017 Jul 23. J Pain Symptom Manage. 2017. PMID: 28743660 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical